We advised Biocytogen on its IPO and HKEX listing

Davis Polk advised Biocytogen Pharmaceuticals (Beijing) Co., Ltd. in connection with its initial public offering and listing of H shares on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A / Regulation S. The gross proceeds from the offering amounted to approximately HK$549 million prior to the exercise of the over-allotment option.

Biocytogen is a clinical-stage biopharmaceutical company with a pipeline of 12 drug candidates, five of which are in the clinical stage. It also has revenue-generating pre-clinical research service businesses. Biocytogen is undertaking a unique and innovative large scale antibody drug discovery program, Project Integrum (千鼠萬抗), that discovers antibody molecules for internal drug development or external monetization. Project Integrum adopts an evidence-based in vivo efficacy screening methodology to generate and screen antibodies against over 1,000 potential antibody drug targets concurrently. Biocytogen has also developed RenMice platforms consisted of two fully human transgenic mice lines to generate a diverse repertoire of fully human monoclonal antibodies and bi-specific antibodies.

The Davis Polk corporate team included partners Xuelin (Steve) Wang and Yang Chu, associate Jennifer Ng and registered foreign lawyer Yi-Ping Chang. Counsel Alon Gurfinkel and associate Kelli A. Rivers provided tax advice. Counsel Sarah E. Kim provided 1940 Act advice. Members of the Davis Polk team are based in the Hong Kong, London and New York offices.

Copy link to share post